1. Introduction {#sec1}
===============

Substance use disorders (SUDs) incur a significant burden to society in the United States and worldwide. In the United States alone, SUDs are estimated to cost \$400 billion across a variety of domains, including crime, poor health outcomes, and lost productivity ([@bib202]). There have been alarming shifts in the clinical presentation where young people are increasingly experiencing more consequences from use as demonstrated by the increases in alcohol-related liver disease ([@bib198]), opioid use disorder ([@bib124]), and marijuana-related vehicle crashes ([@bib20]). These trends collectively point to the importance of targeting specific mechanisms that may facilitate the transition from occasional use to chronic, problematic substance abuse.

Early life stress and cumulative adversity, including child maltreatment, are key factors that play a critical role throughout the cycle of addiction, from the development of addictive disorders, to maintenance, relapse, and recovery from SUDs ([@bib46]; [@bib109]; [@bib177], [@bib176]). There has been limited focus on the potent effects of drug use itself on the acute stress response. Although several studies have pointed to an altered setpoint in these systems, less has focused on effects of these adaptations on cue reactivity, drug motivation, and relapse risk. For this reason, we uniquely focus on the effects of acute and chronic drug use on the biological stress pathways and their related effects on stress, reward, craving, and relapse risk. Previous work has investigated the acute effects of different drugs of abuse in animal models of acute and chronic use ([@bib7]) and translational research on addiction course ([@bib111]). Thus, we focus primarily on human studies and the peripheral stress response and include central reward and motivation pathways when discussing the effects of altered peripheral stress biology on drug motivation and intake. Furthermore, this review covers the most commonly used drugs of nicotine, alcohol, cannabis, psychostimulants (i.e., cocaine and amphetamines), and opioids.

1.1. Relationship between peripheral and central neuroadaptations to drug use {#sec1.1}
-----------------------------------------------------------------------------

The most frequently studied biological stress responses in relation to SUDs include the two branches of the peripheral autonomic nervous system (ANS), specifically the physiologic responses of the sympathetic and parasympathetic arms, and the neuroendocrine responses of the hypothalamic-pituitary-adrenal (HPA) axis (see [@bib137] for review of stress biomarkers). For this review, we will focus on specific measures of ANS (i.e., epinephrine/norepinephrine, heart rate variability \[HRV\]) and HPA axis responses (i.e., adrenocorticotropic hormone \[ACTH\], cortisol/corticosterone; see [Fig. 1](#fig1){ref-type="fig"} for an illustration). The central stress pathways in humans have been described in detail in previous reviews ([@bib115]; [@bib177]) and include interactions between brain stem (Locus Coeruleus \[LC\]; Ventral Tegmental Area \[VTA\]; Substantia Nigra \[SN\]; Dorsal Raphe), limbic (hypothalamus, amygdala, thalamus, and the Bed Nucleus of the Stria Terminali \[BNST\]), striatal (ventral and dorsal) and the insular, anterior cingulate and regions of the prefrontal cortex (PFC), and the sensory and motor cortices, circuits that are involved in the processing of drug and stressful stimuli and in regulating these responses (see [Fig. 1](#fig1){ref-type="fig"}). These central stress pathways have been most commonly implicated by neuroimaging tools in acute drug effects, drug motivation and as risk markers for relapse ([@bib69]; [@bib114]; [@bib179], [@bib177]; [@bib180]).Fig. 1The dynamic interplay between peripheral stress response and central stress circuitry. Autonomic and HPA axis arousal (1) occurs in response to stress and drug use. This arousal causes a peripheral feedback (2) into limbic circuits as well as central activation to initiate adaptive emotional, cognitive and behavioral responses to regulate stress, emotion and reward states (3). Sensory regions provide information to the amygdala, hippocampus, and locus coerulus (LC), which facilitates adaptation to central emotional, cognitive, behavioral responses. AMY = Amygdala, HP=Hippocampus, HYP=Hypothalamus, PFC=Prefrontal Cortex, THAL = Thalamus, VTA=Ventral Tegmental Area. Templates were used from Servier Medical Art ([www.smart.servier.com](http://www.smart.servier.com){#intref1020}).Fig. 1

2. Acute and chronic psychoactive drug effects on peripheral stress responses {#sec2}
=============================================================================

2.1. Nicotine {#sec2.1}
-------------

### 2.1.1. Acute effects of nicotine in non- and light smokers {#sec2.1.1}

The acute effects of nicotine on the HPA axis in non-smokers or light smokers ("chippers") have not been as well-documented, particularly in human samples, as compared to chronic users. Nevertheless, consistent with evidence in non-dependent animals, nicotine increases corticosterone levels particularly at high levels of nicotine dosing ([@bib1]; [@bib26]; [@bib42]; [@bib117]; [@bib147]). Both nicotine-naïve and regular nicotine users show dose-dependent increases in cortisol, ACTH and prolactin have been reported (see [@bib131] for review). Studies of the mechanism in animal models suggest that the effect of nicotine on the HPA axis is primarily through the nicotine-induced release of norepinephrine and CRH in the paraventricular nucleus of the hypothalamus ([@bib63]; [@bib126]; [@bib147]). These collective findings indicate nicotine activates the HPA axis via its direct effects on the catecholaminergic and cholinergic stimulation of the ANS.

Regarding the ANS, naïve or light smokers' catecholamine response has been mostly documented in animal models, but several human studies have studied the cardiovascular effects of nicotine in nonsmokers. Epinephrine has been reliably shown to increase in a dose-dependent fashion in response to nicotine ([@bib73]; [@bib131]; [@bib140]; [@bib218]), particularly under conditions of nicotine self-administration ([@bib42]). Nicotine also increases cardiovascular output in animals ([@bib218]), a finding that has been replicated in non-smoking humans ([@bib57]; [@bib151]). In human models, several studies have demonstrated that nicotine increases cardiovascular activity as measured by increases in low frequency (LF; an index of sympathetic activity), and decreases in high frequency (HF; parasympathetic activity) HRV, both in response to nicotine and when co-administered with a stressor ([@bib94]; [@bib183]).

### 2.1.2. Acute effects of nicotine in chronic, heavy smokers {#sec2.1.2}

Chronic nicotine administration dysregulates tonic levels of the HPA axis. Chronic smokers show greater basal cortisol levels relative to non-smokers ([@bib4]). In chronic users, acute nicotine administration further increases cortisol and ACTH levels ([@bib26]; [@bib136]; [@bib153]; [@bib172]; [@bib221]) in a dose-dependent manner ([@bib84]; [@bib135]). Animal models show that nicotine elevates corticosterone and ACTH early in use but, although nicotine still induced a rise, this response to nicotine was attenuated after successive administration ([@bib26]); a comparison that has been replicated in a correlation study of humans where chronic users are compared to chippers ([@bib175]). Nicotine withdrawal is associated with a higher basal HPA axis tone and blunted response to nicotine at varying lengths of acute abstinence ([@bib31]; [@bib61]). Thus, the HPA axis adapts to the stimulating effects of chronic smoking (see [@bib4] for review) and, during early abstinence, these changes result in an increase of activity that worsens withdrawal.

Heavy smokers also display disruptions in ANS system functioning. Like the HPA axis, acute nicotine administration increases heavy smokers' epinephrine, norepinephrine, blood pressure, and heart rate ([@bib40]; [@bib57]; [@bib84]; [@bib136]; [@bib138]; [@bib188], [@bib187]; [@bib201]; [@bib221]). Acute administration of nicotine also increases LF HRV, decreases HF HRV, and increases the ratio of LF/HF HRV ([@bib8]; [@bib10]; [@bib94]; [@bib101]; [@bib138]). Cigarette chippers have a more robust blood pressure response to nicotine than was noted in heavy smokers ([@bib175]). Sustained abstinence appears to normalize ANS activity as evidenced by decreased epinephrine and norepinephrine levels and reduction in the LF/HF HRV ([@bib138]). Nicotine, therefore, activates the peripheral ANS stress system in both acute response and overall tone that normalizes over sustained abstinence.

2.2. Cannabis {#sec2.2}
-------------

### 2.2.1. Acute effects of cannabis in light users {#sec2.2.1}

Δ1-tetrahydrocannabinol (THC) is the psychoactive component of cannabis. Administration of THC activates corticosterone/cortisol and ACTH in both animal ([@bib105]; [@bib125]; [@bib155]) and human samples ([@bib36]; [@bib87]; [@bib159]). The action of exogenous cannabinoids on the HPA axis is complex, exerting both direct effects ([@bib155]) on both the paraventricular nucleus of the hypothalamus and via other brain areas, including the basolateral amygdala ([@bib7]). Acute smoked cannabis or oral THC stimulate cardiovascular arousal with increases observed in HR and plasma epinephrine ([@bib87]) and increases heart rate ([@bib112]; [@bib194]; [@bib225]).

### 2.2.2. Acute effects of cannabis in heavy users {#sec2.2.2}

Acute administration of smoked cannabis or oral THC in chronic users has also been shown to stimulate both the ANS and the HPA axis. With regard to the HPA axis, cortisol increases in response to either smoking marijuana or receiving intravenous THC has been reported ([@bib33]; [@bib37]; [@bib159]). However, the THC-induced rise in disordered users was blunted when it was compared to the cortisol increase in healthy controls ([@bib37]; [@bib159]). Prolonged exposure to THC over the course of two weeks blunted the cortisol rise expected after administration ([@bib11]). This previous finding combined with observed higher basal cortisol levels in heavy cannabis users ([@bib35]; [@bib98]) and sustained higher levels even after six months of abstinence ([@bib189]) suggest that continued cannabis use is associated with lasting adaptations in the HPA axis. It should be noted that based on these studies, it is unclear if chronic cannabis use alters stress function or vice versa. While some studies have found that THC does not impact epinephrine and norepinephrine concentration ([@bib44]), THC does induce a marked increase cardiovascular response in chronic users ([@bib44]; [@bib77]; [@bib112]; [@bib158]; [@bib207]), but this response does not differ between heavy and light cannabis smokers ([@bib77]). Thus, acute exposure to the psychoactive components of cannabis increases HPA axis activity and cardiovascular arousal, but its effects on peripheral catecholamines are not clear and more research is needed. Abrupt cessation of smoking also caused blood pressure to increase dramatically ([@bib206]); however, the abstinence-related increases in heart rate are delayed ([@bib78]).

2.3. Stimulants {#sec2.3}
---------------

### 2.3.1. Acute effects of stimulants in naïve or light users {#sec2.3.1}

Cocaine increases corticosterone and cortisol in cocaine-naïve rodents ([@bib19]; [@bib110]; [@bib139]; [@bib169]; [@bib170]) and humans ([@bib82]) in a dose-dependent fashion. Similarly, cocaine also increases ACTH in male rodents ([@bib19]; [@bib106]; [@bib110]; [@bib139]), although this was not replicated in the one human study ([@bib82]). Furthermore, it appears that CRF may play an important role in the mechanism of action of cocaine. One study found that CRF, when peripherally administered, blocks the effects of HPA response ([@bib170]). Gender may be an important moderator as indicated by one study that found female rats had a larger corticosterone response to cocaine than male ([@bib106]). This finding is particularly important since most cocaine administration studies in naive populations have focused on male animals and humans. Cocaine also stimulates the ANS as evidenced by increased epinephrine and norepinephrine in an animal sample ([@bib30]) and increased heart rate in a human sample ([@bib208]). In human models, cocaine dramatically increases HR and reduces the activity of the parasympathetic nervous system as evidenced by reduced HF HRV ([@bib208]).

Another group of stimulants, amphetamines, has similar impacts on the HPA axis and adrenergic system. Similar to cocaine, amphetamines increase cortisol responding in human ([@bib38]; [@bib43]; [@bib74]; [@bib91]; [@bib146]; L. M. [@bib148]; [@bib168]; [@bib184]; [@bib216]; [@bib220]) and rodent samples ([@bib100]; [@bib197]). Individuals with a history of using methamphetamine at least six times, but who were not dependent, had increased in cortisol in response to methamphetamine administration ([@bib80], [@bib79]). CRF and other neurotransmitters mediate the cannabis-induced increase in cortisol ([@bib7]; [@bib197]). In addition to its actions on the HPA axis, amphetamine also stimulates adrenergic response as evidenced by increased norepinephrine, blood pressure ([@bib146]), blood pressure ([@bib146]), and heart rate ([@bib38]). Amphetamine acutely activates the ANS of experienced, but not dependent, methamphetamine users as indexed by the norepinephrine metabolite, 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) ([@bib80]).

### 2.3.2. Acute and chronic effects of stimulants in dependent users {#sec2.3.2}

Several studies have demonstrated that cocaine increases corticosterone secretion (see [@bib121] for review). In humans, chronic cocaine users also display higher cortisol and ACTH levels when administered cocaine (see [@bib120] for review) and elevated basal levels of cortisol ([@bib76]) that either are unchanged by abstinence ([@bib128]; [@bib134]) or reduced with sustained abstinence from cocaine ([@bib22]). Cocaine administration also increased the adrenergic response including catecholamine levels ([@bib187]), blood pressure, and heart rate ([@bib48]; see [@bib55] for review; [@bib102]; [@bib104]; [@bib119], [@bib118]; [@bib160]; [@bib211]) dose-dependently ([@bib32]; [@bib56]; [@bib118]). Some studies have suggested that repeated exposure to cocaine sensitizes the heart rate response to cocaine with most robust responses occurring during laboratory-monitored cocaine binges ([@bib102]; [@bib211], [@bib210]). Other studies found that, after an initial rise in the subjective cardiovascular effects, the cardiovascular response flattens suggesting that individuals become tolerant to binge levels ([@bib14]; [@bib56]; [@bib217]). Reed and colleagues' (1984) dissection of the HR response by comparing the area-under-the-curve to the overall increases suggested that the increase in the cardiovascular response may be due to the conditioned response of pairing administration with contextual cues. During acute abstinence, the norepinephrine metabolite MHPG is increased as was systolic blood pressure in response to intranasal cocaine ([@bib128]). Basal cardiovascular levels are elevated in chronic cocaine users ([@bib173]).

The effects of amphetamines on cortisol levels in chronic users is complicated. Regular 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") users had higher hair cortisol levels than light, recent users or non-using controls ([@bib150]). One study found that amphetamine use while on placebo treatment was associated with a significantly lower cortisol level after administration relative to amphetamine-dependent individuals on naltrexone ([@bib92]); however, another study found that methamphetamine-increased cortisol and ACTH in experienced non-dependent users. The effect of amphetamines on basal levels of the HPA axis is not clear-cut. Some studies have found that non-treatment seeking chronic methamphetamine users had lower ([@bib25]) or no differences in basal cortisol levels ([@bib224]) as compared to controls subjects. The latter correlational study found no differences between individuals with methamphetamine dependence and control subjects after four weeks of abstinence. Methamphetamine-dependent individuals had altered sympathetic tone with increased LF HRV, decreased HF HRV, and higher LF/HF ratio, and greater use positively correlated with the latter ([@bib83]). More research is necessary to understand the effects that amphetamines have in stimulant-dependent individuals fully.

2.4. Alcohol {#sec2.4}
------------

### 2.4.1. Acute effects of alcohol in light drinkers/naïve individuals {#sec2.4.1}

Alcohol acutely stimulates the HPA axis in non-dependent users. In rats, alcohol has been shown to consistently increase plasma corticosterone and ACTH levels ([@bib6]; [@bib162]). In humans, similar increases in cortisol have been noted in response to acute alcohol administration ([@bib62]; [@bib67]; [@bib132]; [@bib203]; [@bib90]). It appears the effects of alcohol on the HPA axis occurs primarily due to alcohol\'s actions on the paraventricular nucleus of the hypothalamus ([@bib7]). With respect to ANS activation, animal models have demonstrated elevated epinephrine and norepinephrine response to intravenous alcohol administration ([@bib113]; [@bib152]) and, similar to the observations with the HPA axis in humans, found that alcohol blunted the expected stress response when the animals were confronted with a stressor. In humans, noradrenaline responses were also elevated and peaked about 30 min after drinking 0.9 g/kg of alcohol and remained high after 4 h ([@bib88]). Acute alcohol administration also appears to impact cardiovascular indices of increased sympathetic arousal. Acute alcohol administration in moderate to high doses consistently decreases high-frequency HRV and also increases the ratio of low frequency to high-frequency heart rate variability, an index of sympathetic to parasympathetic function ([@bib165]). Collectively, these results are consistent with animal studies and suggest that alcohol acutely increases HPA axis and ANS activity in naive alcohol users and may further blunt the stress response when administered in close temporal proximity to a stressor.

### 2.4.2. Acute effects of alcohol in binge and alcohol-dependent samples {#sec2.4.2}

Persistent binge drinking alters the HPA axis and ANS system via the repeated activation by frequent, heavy alcohol use. Basal cortisol levels are elevated in binge heavy men ([@bib16]; [@bib199]) and women ([@bib219]). Furthermore, the expected rise in cortisol in response to alcohol administration was blunted in heavy relative to light/moderate social drinkers ([@bib97]). Basal HRV levels appear to significantly lower in heavy drinking males, indicating decreased functioning of the ANS ([@bib199]). Also, individuals who were heavy drinkers five years prior had a reduced cortisol response to alcohol relative to those who were light drinkers ([@bib99]).

Alcohol stimulates cortisol levels in both dependent animals ([@bib162]) and humans ([@bib3]; [@bib50]; [@bib132]; [@bib192]). When an individual abstains from alcohol, withdrawal is also associated with increased basal cortisol levels ([@bib132]) and decreased diurnal variation ([@bib2]; [@bib163]). Cortisol tone also tends to be increased during periods of heavy drinking ([@bib215]). Although basal cortisol levels decrease during longer abstinence ([@bib141]), sustained abstinence is associated with increased basal cortisol levels as compared to healthy controls ([@bib191]). Activation of the ANS system in alcohol-dependent individuals is also affected by alcohol. Acute intoxication was associated with increases in MHPG ([@bib18]) and, as dependent individuals enter acute withdrawal, levels of MHPG decrease as time since their last drink increase ([@bib81]). Although not tested directly in response to acute intoxication, adaptive HRV functioning is also directly modified by alcohol dependence. A meta-analysis found that alcohol dependence, regardless of treatment setting, is associated with a decrease in basal HF HRV levels ([@bib156]). Collectively, the results from these studies point to neuroadaptations in HPA and ANS response with active binge and chronic use such that there is a blunted or lack of a phasic response but elevated tonic levels in binge/disordered users relative to controls.

2.5. Opioids {#sec2.5}
------------

### 2.5.1. Acute effects of opioids in non- and light users {#sec2.5.1}

Unlike other drugs of abuse, opioids appear to have different effects on stress biology in rodent as compared to humans. In rats, morphine increases ACTH and corticosterone ([@bib21]; [@bib45]; [@bib195]) whereas, in humans, morphine dampens the HPA response ([@bib39]; [@bib64]; [@bib164]; [@bib223]). Naloxone, an opioid antagonist, increases ACTH and cortisol levels in humans ([@bib72]; [@bib143]) and pigs ([@bib161]; [@bib167]). There is evidence that opioids directly impact the HPA axis ([@bib209]) to suppress HPA axis responses. The impact of opioids on the ANS is complex, with decreasing response of HPA axis to CRF, morphine had limited impact on the epinephrine and norepinephrine response ([@bib164]). Although opioids decrease heart rate and blood pressure ([@bib195]), high-frequency HRV has been shown to be decreased by opioids ([@bib107]).

### 2.5.2. Chronic effects of opioids on stress systems in dependent samples {#sec2.5.2}

In human samples, opioids and opioid agonists, including methadone and buprenorphine, acutely suppress cortisol levels ([@bib23]; [@bib133]; [@bib145]; [@bib213], [@bib212]) and basal cortisol levels tend to be higher in opioid-dependent users as compared to healthy controls ([@bib213]). One early study found that cortisol was unchanged by heroin administration ([@bib133]); and a more recent study found that diacetylmorphine, the pharmaceutical version of heroin prescribed for maintenance therapy, decreased cortisol levels more so than methadone ([@bib213]). Withdrawal from opioids corresponds with significant tonic increases in ACTH and cortisol levels regardless of whether it was induced by a naloxone challenge ([@bib65]) or occurred naturally over time ([@bib174]). Acute administration of intravenous opioids is associated with an initial spike in heart rate that is followed by a delayed reduction in heart rate ([@bib95]; [@bib166]). A similar pattern of results was found for withdrawal-related effects on the SAM system. Specifically, epinephrine, norepinephrine, LF HRV, and blood pressure increase in response to naloxone-induced withdrawal ([@bib85]; [@bib96]; [@bib127]).

On the basis of the review presented in the previous sections, [Table 1](#tbl1){ref-type="table"} summarizes the direction of phasic HPA axis and ANS responses to acute administration of each psychoactive drug of abuse in naïve/non-disordered and adaptations in these responses with binge/heavy and dependent users relative to controls.Table 1Acute drug response in non-disordered/lightly using subjects and actively using binge/disordered substance users.Table 1SubstanceAcute Drug Response**Binge/Disordered vs.**\
Naïve/Non-Disordered\*HPAANSHPAANSNicotine**↑↑**↓↓Cocaine**↑↑**??Amphetamine**↑ ↓↑**??Cannabis**↑↑**↓↑Alcohol**↑↑**↓↑Opioids**↓↑**??[^1][^2][^3]

3. Drug-related adaptations in stress biology, reward, craving and relapse risk {#sec3}
===============================================================================

The previous sections and [Table 1](#tbl1){ref-type="table"} highlights the potent effects of the most common psychoactive drugs on stress biology with acute effects of stimulation for nicotine, cannabis, stimulant, and alcohol, and depressive effects of acute opioids in humans. More importantly, regular, binge and chronic use of drugs alter these stress responses, signaling significant adaptations in stress biology. As substance use escalates in frequency and intensity, adaptations in HPA axis and ANS pathways manifest as changes in basal levels, but also in phasic responses to drug, stress and challenge (see [@bib4] for review of nicotine; [@bib8]; see [@bib15] for review of alcohol; [@bib129]; [@bib130]). In turn, withdrawal-related basal increases in cortisol are associated with cognitive impairments ([@bib47]). In turn, these cognitive impairments could perpetuate the worsening of addiction (see [@bib12]; [@bib13]; [@bib190] for discussion).

This cumulative evidence begs the question of whether such adaptations in stress biology are the mere consequences of drug use, or if they also serve as interoceptive drug-related adaptations that may play a role in motivating compulsive drug use and relapse risk in chronic users. There have been decades of focus on mesolimbic striatal dopaminergic pathways as critical for the reinforcing effects of psychoactive drugs. While striatal adaptation may drive compulsive drug motivation, other positron emission tomography (PET) evidence indicates that psychoactive drug-stimulated increases in cortisol is highly correlated with dopamine release in the striatum ([@bib17]; [@bib34]; [@bib216]) and drug-induced cortisol increases are associated with the subjective intoxication in healthy volunteers ([@bib148]). Similarly, psychological stress provocation in healthy volunteers has also been shown to increase dopamine transmission in the striatum and the PFC ([@bib144]; [@bib154]), and cortisol responses to psychosocial stressors predict reward after amphetamine administration ([@bib75]). In a functional magnetic resonance imaging (fMRI), a psychological stress provocation results in robust striatal activation, specifically in the ventral striatum but not the dorsal striatum relative to non-stress cues in healthy volunteers ([@bib182]). Also, activity in the ventromedial prefrontal cortex and the rostral anterior cingulate cortex was predictive of resilient coping and low levels of alcohol use. Consistent with these findings, other fMRI studies have shown blunted stress responses in at-risk individuals is predictive of blunted central brain activity in limbic-striatal and prefrontal regions ([@bib24]; [@bib68]) that are critical for regulating motivated behavior and resilient coping. Other PET research has reported a loss of dopamine transmission and blunted dopamine release in drug-abusing patients is correlated with severity of addiction as well as with increases in compulsive motivation for drug and treatment failure ([@bib123]; [@bib122]). Whether these blunted dopamine changes are related to blunted glucocorticoid responses to drug or stress has not been fully investigated. Nonetheless, these data highlight that drug-induced activation of stress and dopaminergic pathways are highly interactive and suggest that both may jointly play a role in psychoactive drug effects, and on compulsive drug motivation.

Findings from several well-controlled laboratory studies in treatment-seeking or non-treatment seeking and acutely abstinent drug-abusing patients have shown a blunted stress cortisol and ANS axis response to stress and drug cue provocations along with higher basal cortisol and HR along with disrupted HRV responses ([Table 2](#tbl2){ref-type="table"}; see [@bib177] and [@bib137] for review). Such responses are predictive of higher relapse risk after treatment and co-occur with greater drug craving during stress and drug cue provocation ([@bib8]; [@bib129]; [@bib137]; [@bib178]; [@bib181]). Blunted cortisol arousal to stress cues is also predictive of increased alcohol motivation to drink alcohol in binge, heavy drinkers ([@bib16]). Thus, these studies consistently link adaptations and changes in peripheral and central stress responses to compulsive drug motivation and relapse risk, thereby suggesting a need to target these pathways as both markers of addiction risk and severity but also in treatment development ([@bib137]).Table 2Basal states and stress- and drug-cue induced responses in substance abusing compared to healthy control subjects.Table 2SubstanceTonic/Basal StateStress ProvocationDrug CuesHPAANSHPAANSHPAANSNicotine↑↑↓↑ = ?↑Cannabis↑↑↓?↓↑Cocaine↑↑↓↑ = ↑ = ↑ = Amphetamine↑ ↓ = ↑↓ = ??Alcohol↑↑↓↓ = ?↑Opioids↑↑↑ ↓↓↑ ?↑[^4][^5]

On the basis of the review presented in previous sections, we present a heuristic model to illustrate the drug-stress motivation cycle in [Fig. 2](#fig2){ref-type="fig"}. The findings presented earlier suggest a *feed-forward* cascade of effects of drugs on stress biology. Our stress biology is wired to help us to adapt to life\'s struggles but, in the face of increasing drug use and abuse, this critical biological process is handicapped and blunted. Consequently, heavy and chronic drug users are more vulnerable to negative affect, distress and poor stress coping. Furthermore, with blunted or more "tolerant" stress responses to drug use, greater levels of drug use are needed to maintain allostasis, thereby driving a cycle of increased drug use and stress disruption that further drive greater compulsive drug motivation and relapse risk.Fig. 2A heuristic framework for drug-induced stress and reward interactions is presented to illustrate the effects and acute and chronic drug intake on the stress biology and their effects on drug motivation and compulsive drug use. **A** refers to the effects of acute drug use or stress on peripheral and central stress response in light or inexperienced drug users. **B** describes the central striatal-prefrontal effects in these healthy individuals that encode drug learning, neuroflexibility, and resilient coping that results in controlled, low levels of drug intake in light drug users with robust stress responses. **C** indicates the mediating process of increased binge and heavy use that results in an altered and blunted stress and reward response in vulnerable individuals. **D** shows the blunted response then results in the feed-forward cascade of increased craving, neuroendocrine tolerance, and acute abstinence/withdrawal effects that play a role in compulsive drug use and relapse risk. **E** highlights potential moderators that make individuals more vulnerable or more resilient in each of the previous processes.Fig. 2

4. Factors affecting drug effects on stress responses {#sec4}
=====================================================

4.1. Effects of drugs on responding to a stressor {#sec4.1}
-------------------------------------------------

We focused specifically on the effect of drugs on the activity of the HPA axis and the SAM system in the previous sections; however, anecdotal evidence from patients and several theories of substance use point to the fact that a stressor often precedes use, thus likely modifying the response to the stressor. In an experimental model of this observation, studies have shown that the simultaneous administration of a drug with a stressor disrupts the normal stress response system ([@bib205]). For example, when alcohol or methamphetamine is administered following a stressor, the drug impairs the cortisol response to psychosocial and pharmacological stressors ([@bib27]; [@bib184]). Alcohol administered immediately after a stressor prolonged the negative affect and increased craving in response to the stressor ([@bib28]). When low doses of THC was administered after a stressor, the subjective distress was also blunted; however, at high doses of THC, negative affect was increased, and blood pressure was blunted ([@bib29]). In a human laboratory model of smoking relapse, exposure to a stressor increased the rewarding effects of smoking, which was correlated to cortisol ([@bib129]). However, these effects may depend on the type of drug administered. In opioids, cortisol administration was found to reduce craving in patients with low-dose heroin consumption ([@bib214]). This finding is perhaps not surprising given that opioids have a dampening effect on the HPA axis system whereas the other substances of abuse have an activating effect. Further research is necessary to fully understand the interactive impact of a drug and stress on stress system responsivity.

4.2. Drug-related factors influencing stress responses {#sec4.2}
------------------------------------------------------

A host of methodological factors (e.g., frequency and amount of recent drug use, rapidity and amount of acute drug intake, the dose of the drug administered and tested, type of drug within a broad drug class, route of administration) could potentially impact the strength of the drug effects on the stress responses. Notably, Allain et al. (2015) discuss the role of frequency of drug use and rapidity of use during bouts as significant aspects of compulsive drug seeking and addiction risk. Self-motivational aspects of how often drug is used and the use topography may influence both subjective drug effects, drug-related stress responses, and drug motivation for continued drug use.

In other research, King and colleagues found that high dose alcohol (0.8 g/kg) increased cortisol levels in light drinkers whereas a low dose of alcohol (0.4 g/kg) did not and that heavy binge drinkers showed blunted cortisol responses ([@bib97]). On the other hand, [@bib16] showed low levels of alcoholic beer consumed under a behavioral motivation paradigm increased cortisol in both moderate non-binge and binge-heavy users. The articles reviewed here use a variety of administration methods, including intravenous, intranasal, oral, and self-administration. Each route has differences in the rate of absorption which would have different impacts on the reactivity of the stress systems ([@bib70]). Another important methodological consideration is the impact of recent drug use history on the acute drug responses. For example, [@bib157] found that increased drinking in the past month before participating in the study predicted the acute subjective and psychomotor response after an intravenous alcohol administration. Most studies that have investigated the effect of drugs on the stress systems have required that individuals remain abstinent for a certain period prior to participating in the study; however, some individuals may choose to begin abstinence in advance of their participation and, thus, may have differential responses to drug administration depending on their length of abstinence. Relatedly, given the impact of withdrawal on the HPA axis, it is also likely that the stress system response to drug administration may also vary depending on their stage of withdrawal.

4.3. Factors that influence the response to stress {#sec4.3}
--------------------------------------------------

[Family History]{.ul}: Other studies suggest that participant factors, such as a family history of alcohol use disorder, may also play a role. Non-dependent participants with a family history of alcohol use disorders have consistently displayed an alcohol-induced reduction in cortisol and ACTH relative to individuals without such a family history ([@bib171]; [@bib222]). Collectively, findings from these studies suggest that individuals who may be genetically predisposed already show patterns of reactivity like dependent users.

[Co-Occurring Drug Use]{.ul}: Most of the research studies discussed in this article focused on samples that were dependent on a single drug; however, most individuals who seek treatment for substance use disorders report abusing several different types of drug or have a history of dependence on other substances. Individuals with marijuana use experience greater reinforcing effects of nicotine use ([@bib151]). Combined administration of cocaine and marijuana results in an increased cardiovascular response and poor cognitive performance as compared to the effect of either drug alone ([@bib55], [@bib54]; [@bib53]; [@bib52]). Other studies have found that combined use of cannabis with MDMA results in an enhanced acute subjective and stress system response to the drugs ([@bib44]; [@bib103]). Findings from our laboratory indicate that a history of marijuana dependence with alcohol or cocaine use dysregulates HPA axis responding to stress- and drug-related cues ([@bib60]). Nicotine increases the self-administration alcohol ([@bib9]) and, at low doses of nicotine, increases the alcohol-induced dopamine release in the VTA ([@bib200]). Despite this, we know little about the impact of polysubstance disorders or other past drug history has on the HPA axis and ANS response to drugs.

[Gender:]{.ul} Drug response may also differ by gender. Women, overall, tend to report greater sensitivity to drug effects as compared to men. For example, women tend to show greater sensitivity to the negative effects of intravenous nicotine administration as compared to men ([@bib40]; [@bib185]), and men tend to show greater initial reward sensitivity intranasal administration of nicotine ([@bib151]). In response to cocaine, women reported greater anxiety following administration ([@bib104]) and reduced high ([@bib119]) as compared to men. Men tend to have higher amphetamine-induced dopamine release in striatal regions and report correspondingly more rewarding effects of the drug as compared to women ([@bib142]). The effects of these drugs in women may also vary across the menstrual cycle. Alcohol metabolism differs across the menstrual cycle, such that faster rates of elimination are noted in the mid-luteal phase as compared to the early follicular and ovulatory phases ([@bib196]). Women in the luteal phase of their cycle showed decreased responses to cocaine ([@bib186]), nicotine ([@bib40]), and amphetamine ([@bib93]) as compared to those in their follicular cycle. Although one study found limited effects of sex and menstrual cycle on the response to intranasal cocaine ([@bib32]). These collective results suggest that neuroactive steroids, such as estrogen and progesterone, play an important role in the metabolism and effects of drug administration.

[Developmental Stage and Early Trauma]{.ul}: There is evidence that blunted stress reactivity is a predictor of earlier use of substances ([@bib49]; [@bib89]), and that individuals with a blunted cortisol response to stress are at increased risk for substance use ([@bib115]). However, it is unclear if this blunted responding becomes exacerbated by exposure to drugs and at what developmental periods are at-risk individuals most vulnerable. Exposure to early life adversity has known impacts on the HPA axis ([@bib116]) and increases the likelihood that these individuals will develop addictive disorders later in life ([@bib41]; see [@bib46] for review; [@bib66]). Early life adversity is positively associated with dopamine response to amphetamine in the ventral striatum ([@bib149]) and lower gray matter volume in limbic regions in individuals in treatment for substance use disorders and also predicted a shorter time to relapse, regardless of type of drug ([@bib204]). In cocaine-dependent individuals, early life adversity increased the cortisol response to stress although there was no healthy control to determine if this response was blunted ([@bib51]). A recent study found that early life adversity moderated the impact of withdrawal on stress system response to a stressor ([@bib5]). However, few studies have tested these associations systematically in response to stress, and even fewer still have assessed the impact of early life adversity in response to administration of drugs.

5. Conclusions and future directions {#sec5}
====================================

Intake of psychoactive drugs has significant acute effects on the peripheral stress pathways. These effects parallel drug-related effects on central stress and reward pathways to alter acute drug-related subjective, neuroendocrine, and physiological states. Regular, high levels of drug use alter stress and reward responses both in tonic and phasic responding and recent findings suggest that such alterations are significantly associated with the tolerance, withdrawal and intoxication effects of drugs as well as in predicting current drug use and future relapse. This review suggests that addictive substances, although varying in neurobiological targets of action, are similar in having a significant and potent effect on stress pathways, to affect stress responses, craving, and drug intake.

However, it should be noted that there are limits to what can be concluded from the current literature and important areas for future research. Most studies discussed here have focused entirely on either naïve participants/light users or chronic/dependent users; only a few have compared across different types of users. For those that have compared across substances, chronic use is generally associated with a blunting of the drug-induced activation of the stress systems ([@bib86]; [@bib97]; [@bib193]; [@bib199]); however, this has not been fully elucidated in many drugs. More research comparing light users to heavy users is necessary to understand the neuroadaptations that occur to drug administration fully. Additionally, most studies compare stress reactivity in chronic substance users to healthy controls are cross-sectional. Thus, it cannot be determined if the stress dysregulation of heavy users is caused by chronic exposure to substances or predisposes them to future drug use. It is probably, and indeed very likely, that the effect is synergistic. Individuals with a disrupted stress response, due to early trauma or family history, are more likely to abuse drugs, which in turn further dysregulates their stress response. Thus, longitudinal research, such as the massive undertaking that is the Adolescent Brain Cognitive Development (ABCD) study, is vital for determining if drug use results in adaptations to the stress response system or exacerbates pre-existing stress dysregulation. Chaplin and colleagues in this special issue address these temporal associations in an excellent overview of the developmental aspects of the link between substance use and stress response dysregulation.

Substance-related adaptations to the stress system may occur along a continuum. By artificially focusing on one end of the spectrum or the other, we may not be capturing the full spectrum of neuroadaptations in the stress response to addictive substances. Animal models to some extent can address this continuum but, such as seen in opiates ([@bib7]), the stress system response to drug intake may differ between animals and humans. A future review should synthesize findings across species. Finally, certain individual differences, some of which have been noted above, may hasten or slow down the progression along this continuum.

Despite the gaps in the literature, these findings collectively suggest that dysregulation of the stress responses may serve as potential markers for prevention efforts and a target for the development of therapeutic interventions ([@bib71]; [@bib137]). Prevention efforts that target individuals with certain risk factors known to impact the stress system (e.g., early life adversity, genetic, family history) may reduce the likelihood that these individuals will develop a substance use disorder. Concerning treatment efforts for individuals with addictive disorders, the extant treatments are modestly effective at best. There is preliminary evidence that pharmacological interventions that target the adrenergic system may reduce craving evoked by both drugs and stress ([@bib58]; [@bib59]; [@bib108]; [@bib137]). Behavioral treatments that address the management of stress-related craving could enhance the efficacy of existing treatments. Thus, identifying specific biomarkers related to dysregulated stress responses might allow us to identify novel treatment approaches targeting normalizing of the stress response to improve addiction treatment efforts.
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[^1]: Note: In autonomic nervous system activity, LF HRV is indicative of an activated sympathetic nervous system response, whereas HF HRV is reflective of parasympathetic response. Here, we focused on activation of the sympathetic nervous system within the autonomic nervous system.

[^2]: \* Acute phasic effects of drugs on the HPA axis and the ANS in non-disordered/lightly using (non-weekly use at very low levels) subjects as compared to actively using binge/disordered users.

[^3]: ↑ indicates activation; ↓ indicates reduction; ↑ ↓ indicates mixed results; = indicates similar responses; ? indicates areas for future research.

[^4]: Note: A comparison of the tonic levels and acute/phasic effects of stress and drug cues exposure on the HPA axis and the ANS in non-disordered healthy controls chronic, binge/substance abusing individuals (not in acute abstinence or withdrawal). In autonomic nervous system activity, LF HRV is indicative of an activated sympathetic nervous system response, whereas HF HRV is reflective of parasympathetic response. Here, we focused on activation of the sympathetic nervous system within the autonomic nervous system.

[^5]: ↑ indicates activation; ↓ indicates reduction; ↑ ↓ indicates mixed results; = indicates similar responses; ↑ ? = limited evidence, needs more research; ? indicates areas for future research.
